BioNTech to Host Innovation Series R&D Day on November 14, 2024
October 31 2024 - 7:45AM
UK Regulatory
BioNTech to Host Innovation Series R&D Day on November 14, 2024
MAINZ, Germany, October 31,
2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX,
“BioNTech” or “the Company”), will host an edition of the Company’s
Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time
(16:30 p.m. CET) on Thursday, November 14, 2024 in New York City,
U.S.
On the day, BioNTech’s leadership team will
provide an overview of the Company’s corporate strategy and
clinical progress across its pipeline.
Investors, analysts and the interested public
are invited to join the event online via this link.
A replay of the webcast will be available
shortly after the conclusion of the event and archived on the
Company’s website for one year following the call. The public may
also access the presentation slides via the “Events &
Presentations” page of the Investor Relations section of the
Company’s website at www.BioNTech.com.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next
generation immunotherapy company pioneering novel therapies for
cancer and other serious diseases. BioNTech exploits a wide array
of computational discovery and therapeutic drug platforms for the
rapid development of novel biopharmaceuticals. Its broad portfolio
of oncology product candidates includes individualized and
off-the-shelf mRNA-based therapies, innovative chimeric antigen
receptor (CAR) T cells, several protein-based therapeutics,
including bispecific immune checkpoint modulators, targeted cancer
antibodies and antibody-drug conjugate (ADC) therapeutics, as well
as small molecules. Based on its deep expertise in mRNA vaccine
development and in-house manufacturing capabilities, BioNTech and
its collaborators are developing multiple mRNA vaccine candidates
for a range of infectious diseases alongside its diverse oncology
pipeline. BioNTech has established a broad set of relationships
with multiple global and specialized pharmaceutical collaborators,
including Biotheus, DualityBio, Fosun Pharma, Genentech, a member
of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and
Regeneron.
For more information, please visit
www.BioNTech.com.
CONTACTS
Investor Relations
Michael Horowicz
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
BioNTech (TG:22UA)
Historical Stock Chart
From Nov 2024 to Dec 2024
BioNTech (TG:22UA)
Historical Stock Chart
From Dec 2023 to Dec 2024
